source
- Silence Therapeutics’ Phase 2 Trial Shows Strong Efficacy of divesiran in Polycythemia VeraSilence Therapeutics reported that its siRNA candidate divesiran met the primary endpoint in a phase 2 study of patients with polycythemia vera. The trial enrolled 48 participants and 88% of those…
- Sionna’s cystic fibrosis candidate misses primary endpoint in Phase 2 trial, shares plungeSionna Therapeutics announced that its experimental cystic fibrosis drug SION-719 failed to meet the primary endpoint in a Phase 2 trial that added the drug to Vertex Pharmaceuticals' Trikafta. Th…